SCHEDULE 13G/A: L1 Capital Global Opportunities Master Fund Increases Stake in Aptevo Therapeutics to 4.99% Through Warrant Holdings

L1 Capital Global Opportunities Master Fund, Ltd. has filed an amended Schedule 13G, disclosing a 4.99% beneficial ownership stake in Aptevo Therapeutics Inc. through warrants.

Summary

• L1 Capital Global Opportunities Master Fund, Ltd. has filed an Amendment No. 1 to its Schedule 13G, reporting beneficial ownership of 277,000 warrants in Aptevo Therapeutics Inc.
• This reported amount represents 4.99% of Aptevo Therapeutics Inc.'s Common Stock.
• The filing indicates that the 277,000 warrants are subject to a 4.99% beneficial ownership limitation.
• An additional 123,000 warrants, also subject to a 4.99% beneficial ownership limitation, are not included in the reported 277,000 warrants.
• The percentage of class is based on 5,547,214 Common Stock outstanding immediately after a recent offering, as per the Issuer's Prospectus Supplement filed on April 22, 2025.
• The initial Schedule 13G was filed on April 7, 2025, covering 200,000 shares of Common Stock purchased on April 2, 2025.
• L1 Capital Global Opportunities Master Fund, Ltd. is a Cayman Islands-based entity, and its directors, David Feldman and Joel Arber, disclaim beneficial ownership for other purposes.

Sentiment

Score: 6

Explanation: The filing indicates an institutional investor's increased stake in the company, which is generally a positive signal of confidence. However, the passive nature of the 13G filing (under 5% ownership and no intent to influence control) suggests a limited direct impact on company operations or strategy.

Positives

• An institutional investor, L1 Capital Global Opportunities Master Fund, Ltd., has taken a significant stake in Aptevo Therapeutics Inc., which can be interpreted as a vote of confidence in the company's prospects.
• The acquisition of warrants suggests a belief in potential future upside for Aptevo Therapeutics Inc.'s stock.

Future Outlook

The document does not contain any forward-looking statements or guidance from Aptevo Therapeutics Inc. or L1 Capital Global Opportunities Master Fund, Ltd. regarding future performance or strategic direction.

Management Comments

• "By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §§ 240.14a-11." David Feldman, Director of L1 Capital Global Opportunities Master Fund, Ltd.

Industry Context

This Schedule 13G filing indicates a passive investment by an institutional fund in a biotechnology company. Such filings are routine disclosures when an investor's beneficial ownership crosses certain thresholds (e.g., 5%) but does not intend to influence or change control of the issuer. For a biotech company like Aptevo Therapeutics, an institutional investment can signal market confidence in its drug pipeline or strategic direction, even if the investor's role is passive.

Stakeholder Impact

• Shareholders: The disclosure of an institutional investor's stake may positively influence market perception and potentially stock price, signaling confidence in the company.

Key Dates

Recommendation

Keywords

Aptevo Therapeutics, L1 Capital Global Opportunities Master Fund, Schedule 13G, Beneficial Ownership, Warrants, Common Stock, SEC Filing, Institutional Investment, Biotechnology, Pharmaceuticals